Cynosure (CYNO) Gets FDA Clearance for Cellulaze Workstation
Tweet
Share
E-mailGet Alerts CYNO Hot Sheet
Join SI Premium – FREE
Cynosure, Inc. (Nasdaq: CYNO) today announced that the U.S. Food and Drug Administration has cleared the Company's Cellulaze Workstation for commercial distribution, giving millions of American women the first minimally invasive solution in their battle against cellulite.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acrivon Therapeutics (ACRV) Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Digital Realty Trust (DLR) Appoints Susan Swanezy to its Board
- Rimini Street (RMNI) Appoints Steve Hershkowitz as Chief Revenue Officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
